Compare · NVO vs ROIV
NVO vs ROIV
Side-by-side comparison of Novo Nordisk A/S (NVO) and Roivant Sciences Ltd. (ROIV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and ROIV operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 7.1x ROIV ($24.59B).
- ROIV has been more active in the news (12 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 20 for ROIV).
- Company
- Novo Nordisk A/S
- Roivant Sciences Ltd.
- Price
- $38.82-1.05%
- $33.51-1.59%
- Market cap
- $173.66B
- $24.59B
- 1M return
- -
- -16.18%
- 1Y return
- -
- +94.15%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 4
- 12
- Recent ratings
- 25
- 20
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Roivant Sciences Ltd.
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank
Latest ROIV
- Roivant Sciences downgraded by Wolfe Research
- Amendment: SEC Form SCHEDULE 13D/A filed by Roivant Sciences Ltd.
- SEC Form 4 filed by Roivant Sciences Ltd.
- SEC Form 4 filed by Roivant Sciences Ltd.
- CEO Gline Matthew covered exercise/tax liability with 76,171 shares, decreasing direct ownership by 0.46% to 16,583,774 units (SEC Form 4) to satisfy withholding tax
- President and Vant Chair Torti Frank increased direct ownership by 0.30% to 13,495,893 units (SEC Form 4) to satisfy withholding obligation
- President & CIO Sukhatme Mayukh covered exercise/tax liability with 46,879 shares, decreasing direct ownership by 0.25% to 18,583,860 units (SEC Form 4) to satisfy withholding tax
- President & Immunovant CEO Venker Eric sold $7,324,000 worth of shares (200,000 units at $36.62) as part of a pre-agreed trading plan and exercised 200,000 shares at a strike of $3.85 (SEC Form 4)
- Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
- Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus